Pfizer Says 2004 Earnings On Target Despite Neurontin Generics
This article was originally published in The Pink Sheet Daily
You may also be interested in...
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.